Home / Health / Diabetes Drug's Rare Eye Risk Stops Patient's Treatment
Diabetes Drug's Rare Eye Risk Stops Patient's Treatment
9 Sep
Summary
- Woman with type 2 diabetes declined Ozempic due to rare side effect.
- The rare side effect involves permanent vision loss risk.
- Patient prioritizes eyesight over potential weight loss benefits.
A patient diagnosed with type 2 diabetes, identified as Jane, declined a prescription for Ozempic despite her doctor's approval. She had been hopeful that Ozempic would help manage her blood sugar and weight, as she had heard positive success stories.
However, during consultations, her doctor mentioned potential side effects. While common side effects include nausea and digestive issues, the article highlights a rare risk of non-arteritic anterior ischemic optic neuropathy (NAION). This condition can lead to sudden, permanent vision loss in one or both eyes.
Jane decided the extremely rare risk to her eyesight was too significant, stating she would "rather be fat" than risk her vision. Novo Nordisk, the manufacturer, asserts that current data does not suggest a causal relationship between semaglutide and NAION, maintaining the drug's favorable benefit-risk profile.
